Ifezuntirgene inilparvovec

Gene therapy / editing

Also known as AMT-130

Filedunder review

Evidence outlook · regulatory review

Huntington's Disease: application under FDA review, decision date 2027-05-01

FDA grants priority review to ifezuntirgene inilparvovec BLA (2026-11-02). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (2)
Huntington's Disease

Competitive landscape

This drug's own stage for Huntington's Disease: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ifezuntirgene Inilparvovec: this drugPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
Valbenazine (Ingrezza)ApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
TanruprubartPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
WVE-003Phase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
BrezosiranPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
RG6662
—(overall)
Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ifezuntirgene inilparvovec to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (2)
March 2029 (1)
Phase 1/2Huntington's DiseaseActive not recruiting
Est. primary completion 2029-03 · NCT05243017 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Huntington's DiseaseActive not recruiting
Est. primary completion 2029-06 · NCT04120493 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 May 2027FDA action datePDUFA target action date of 2027-05-01 set for ifezuntirgene inilparvovec BLA
US, FDA · Source ↗

Recent

2 November 2026Filing acceptedFDA accepts BLA for ifezuntirgene inilparvovec in Huntington's disease
US, FDA · Source ↗
2 November 2026Priority reviewFDA grants priority review to ifezuntirgene inilparvovec BLA
US, FDA · Source ↗
29 September 2026Topline result36- and 48-month data from Phase I/II studies of AMT-130
2 September 2026Filing submitteduniQure submits BLA for accelerated approval of AMT-130 in Huntington's disease
US, FDA · uniQure · Source ↗
Q3 2026Filing submittedMAA submitted to the MHRA
UK, MHRA · Source ↗
Q3 2026Filing acceptedMHRA validates the MAA
UK, MHRA · Source ↗